Viral vectors for dendritic cell-based immunotherapy
- PMID: 11286712
- DOI: 10.1016/s1471-4906(00)01813-5
Viral vectors for dendritic cell-based immunotherapy
Abstract
Transduction of dendritic cells (DCs) by viral vectors genetically engineered to express tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction allows the control of DC quality, antigen quantity and site of DC reinjection. This review evaluates the viral vectors currently being developed for use in DC-based immunotherapy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources